The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.
FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...
After their marriages broke down, Lauretta and Sharon Gavin decided to move in together and co-parent. This is how they make ...
The Ridin’ For Kids Foundation has announced the child that will be benefiting from their 2025 fundraiser event.
Woman's World on MSN14d
Itchy Rash + Joint Pain? It May Be Dermatomyositis, an Inflammatory DiseaseIf you experience persistent muscle weakness, fatigue and skin changes that don't seem to fade, it could be more than just ...
Hereditary predisposition is a relevant cause of cancer in children and adolescents. At least 10% of all pediatric tumors are due to germline mutations in cancer predisposition genes. Although Cancer ...
Several known risk factors of Dermatomyositis (DM) include female sex, genetics, ultraviolet radiation, prior respiratory disease, viral and bacterial infections, medications, and pollutants and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback